Gene therapy and cell reprogramming for the aging brain: achievements and promise.
In the central nervous system, cholinergic and dopaminergic (DA) neurons are among the cells most susceptible to the deleterious effects of age. Thus, the basal forebrain cholinergic system is known to undergo moderate neurodegenerative changes during normal aging as well as severe atrophy in Alzheimer's disease (AD). Parkinson's disease (PD), a degeneration of nigro-striatal DA neurons is the most conspicuous reflection of the vulnerability of DA neurons to age. Overall, there is growing evidence that a progressive decline in cognitive function and central DA activity represents basic features of normal aging both in humans and laboratory rodents. Spontaneous or environmental neurotoxin-mediated exacerbation of these processes contributes to the symptoms of AD and PD, respectively. In this context, neurotrophic factors that can prevent or delay the decline in cognitive function and central DA activity are of clinical interest. Among them, Insulin-like Growth Factor I and Glial cell line-Derived Neurotrophic Factor are emerging as powerful neuroprotective molecules. This article discusses the experimental evidence supporting the neuroprotective relevance of these and related factors in the aging brain. The availability of induced pluripotent stem cells offers a new promise for the treatment of pathologies associated with the loss of specific cell types as for instance, nigral DA neurons (in PD) or basal forebrain cholinergic neurons (BFCN) in the early stages of AD. Recent studies documenting the use of cell reprogramming for the generation of multipotent neuronal precursors as well as functional BFCN and DA neurons are reviewed.
Joaquín
J
Pardo
Gustavo R
GR
Morel
Mariana
M
Astiz
José I
JI
Schwerdt
Micaela L
ML
León
Silvia S
SS
Rodríguez
Claudia B
CB
Hereñú
INIBIOLP, Faculty of Medicine, UNLP, CC 455, 1900 La Plata, Argentina. goya@isis.unlp.edu.ar.
Rodolfo G
RG
Goya
D000544:Alzheimer Disease / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D001921:Brain / Q000378:metabolism / Q000473:pathology; D065150:Cellular Reprogramming; D059329:Cholinergic Neurons / Q000378:metabolism / Q000473:pathology; D059290:Dopaminergic Neurons / Q000378:metabolism / Q000473:pathology; D015316:Genetic Therapy; D051100:Glial Cell Line-Derived Neurotrophic Factor / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000235:genetics / Q000378:metabolism; D010300:Parkinson Disease / Q000235:genetics* / Q000473:pathology / Q000628:therapy
D051100:Glial Cell Line-Derived Neurotrophic Factor; D007334:Insulin-Like Growth Factor I